This compound is a pharmaceutical intermediate specifically designed for the synthesis of adenosine analogs. It features a purine ring system with an iodine substituent and multiple polar functional groups, making it a key building block in nucleoside analog manufacturing.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 141018-29-3
NECA
adenosine receptor agonist
(2S,3S,4R,5R)-2-[(2-fluorophenyl)sulfanylmethyl]-5-[6-[[(1R,2R)-2-hydroxycyclopentyl]amino]purin-9-yl]oxolane-3,4-diol
Pharmaceutical intermediate for adenosine analogs
8-Bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one
pharmaceutical intermediate
TERT-BUTYL N-[(1S)-1-(BENZYLCARBAMOYL)-2-HYDROXYETHYL]CARBAMATE
peptide synthesis intermediate
(R)-Tetrahydropapaverine N-acetyl-L-leucinate
pharmaceutical raw material
(1S,4R)-4-[(2,5-Diamino-6-chloro-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol
Pharmaceutical intermediate for abacavir
(2S,3S,4R,5R)-5-(6-amino-2-iodopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
YEBHQRSEUJCFMN-QMWPFBOUSA-N
CCNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)I)N)O)O